SUVENPHAR.BO BSE

Suven Pharmaceuticals Limited functions as a global biopharmaceutical enterprise, with a strong presence in markets including India, the United States, and Europe. The company's core activities involve the development, production, and distribution of critical pharmaceutical components such as novel chemical entity (NCE) intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and finished drug products. These services are rendered through contract research and manufacturing engagements for pharmaceutical, biotechnology, and chemical sector clients. Established in 2018 with its main office in Hyderabad, India, Suven Pharmaceuticals Limited was initially a subsidiary of Jasti Property and Equity Holdings Private Limited. As of September 29, 2023, its ownership structure changed, and it now operates as a subsidiary of Berhyanda Limited.